The present paper aims to provide experts' consensus on diagnosis and management of cow's milk protein allergy (CMPA) among infants and children in Turkey, based on review of available evidence-based guidelines, publications and experts' clinical experience. The experts agreed that CMPA diagnosis should be based on symptomatic evaluation and diagnostic elimination diet as followed by implementation of an open challenge test after disappearance of symptoms and confirmation of CMPA diagnosis in re-appearance of symptoms. For breastfed infants, differential diagnosis involves withdrawal of cow's milk-containing products from the mother's diet, while calcium supplements and appropriate dietary advice are given to mothers to prevent nutritional deficiency. For infants not breastfed exclusively, cow's milk-based formula and any complementary food containing cow's milk protein (CMP) should be avoided. The first line treatment should be extensively hydrolyzed formula (eHF) with use of amino acid-based formula (AAF) in severe cases such as anaphylaxis, enteropathy, eosinophilic esophagitis and food protein induced enterocolitis along with cases of multiple system involvement, multiple food allergies and intolerance to eHF. Introduction of supplementary foods should not be delayed in CMPA, while should be made one by one in small amounts and only after the infant is at least 17 weeks of age. Infants who are at-risk can be identified by family history of atopic disease. Exclusive breastfeeding for 4-6 months (17-27 weeks) is recommended as the best method of infant allergy prevention. There is no evidence that modifying the mother's diet during pregnancy and/or breast-feeding and delaying solid or even potentially allergic foods beyond 4-6 months in infants may be protective against allergy among at-risk infants. When exclusive breastfeeding is not possible, at-risk infants should get a partially or extensively hydrolyzed formula (pHF or eHF) to prevent allergy until risk evaluation by a health professional. In conclusion, the present consensus statement provides recommendations regarding diagnosis, prevention and management of CMPA in infants and children in Turkey, and thus expected to guide physicians to optimize their approach to CMPA and decrease burden of the disease on infants and their caregivers.
Food allergy is a reproducible specific immune response to the exposure to a given food 1 . Cow's milk protein allergy (CMPA) is a clinically abnormal reaction to cow's milk protein (CMP) via immune mechanisms triggered by milk protein 2 . According to the European Academy for Allergy and Clinical Immunology (EAACI) and the World Allergy Organization (WAO), a hypersensitivity reaction to cow's milk involving the immune system can be called as CMPA 3 . In this regard, involvement of immune system differentiates CMPA from non-allergic cow's milk intolerance (lactose intolerance) which occurs as a result of lactase deficiency without involvement of the immune system 2, 4 .
CMP is the most common cause of food allergy in infants and young children aged younger than 3 years 5 . CMPA associated with gastrointestinal symptoms only can be observed in all age groups 5 . Based on the type of immune reaction responsible for development of CMPA, CMPA is categorized into immunoglobulin (Ig)E mediated, non-IgE mediated, or mixed CMPA 5, 6 .
IgE-mediated CMPA manifests as phenotypical expression of atopy, with or without atopic eczema, allergic rhinitis and/or asthma in most children with CMPA, while non-IgE mediated reaction occurs in a subset of patients mainly with gastro-intestinal manifestations in response to cow's milk ingestion 7 .
Presence of sufficient awareness of the fact that prevention of CMPA is possible by following guidelines for the diagnosis and management of the condition is important given the considerable burden placed by the symptomatic manifestations of CMPA on both the infant and their parents 8 .
Without an appropriate diagnostic workup, a risk for both over and under-diagnosis and thus over and under-treatment has been considered likely in CMPA patients, which restricts the introduction of appropriate diet and maintenance of normal growth and development. For this reason, availability of evidence-based guidance seems critical to be able to manage the disease and to advise parents properly 5, 9 .
Although evidence-based guidelines as well as consensus reports are available in the literature considering the diagnosis and management of CMPA 1,2,5,7,8,10-13 , there are no regionspecific recommendations representing local experiences and challenges for the prevention, diagnosis, and treatment of CMPA in Turkey. Therefore, the present paper aims to provide a consensus statement on the diagnosis, treatment and follow-up of CMPA among infants and children in Turkey.
Material and Methods
An expert panel consisting of 4 pediatric gastroenterology and 2 pediatric allergy specialists from university hospitals met for two meetings to develop consensus opinion on the diagnosis, treatment and follow-up of CMPA in Turkey. The panel critically analyzed recommendations from international guidelines, review articles and published results of randomized control trials for diagnosis, treatment and follow-up of infant and childhood CMPA. Following consideration of the validity, clinical relevance, and applicability of the evidence for CMPA in the Turkey, the panel achieved agreement on a series of recommendations supported by scientific evidence and experts' clinical opinion.
Epidemiology of CMPA
Although no comparable international epidemiological data on CMPA prevalence exists because of different methods and geographical regions in clinical evaluation 7 , data from cohort studies and meta-analyses revealed an overall 1.9% to 4.9% prevalence of CMPA among children with a peak in prevalence (2-3%) in the first year of life and prevalence of <1% in children aged ≥6 years 4, 7, [14] [15] [16] [17] . Parents notice CMPA in their children much more frequently than can be confirmed by appropriate tests, and symptoms suggesting adverse reactions to CMP occur in a 5% to 15% of infants exceeding the true estimates of CMPA prevalence 18 . Therefore, an accurate diagnosis of CMPA is important to prevent infants from being put on inappropriate elimination diets 13, 19 .
Prognosis of CMPA in infancy is good; remission rate is reported to be up to 85-90% at 3 years with better prognosis in cases of gastrointestinal symptoms 19 .
Clinical manifestations of CMPA
CMPA can produce a range of symptoms varying in intensity in infants including ''immediate'' (early; from minutes after allergen ingestion up to 2 hours) reactions and ''delayed'' (late; up to 48 hours to a few weeks following ingestion) reactions 5, 20 .
As summarized in Table I 20 , given the clinical presentations typical for each type of immune reaction, CMPA is categorized into IgE-mediated, non-IgE mediated or mixed type CMPA 5, 20 . Symptoms and signs of CMPA may be related to the skin, the gastrointestinal tract and the respiratory tract 5, 20 . They are variable, mostly nonspecific including oral and perioral swelling, dysphagia, food impaction (e.g. impaired esophageal motility), regurgitation, vomiting, diarrhea with or without malabsorption or protein loss due to enteropathy, persistent constipation often with perianal dermatitis and/or fissure, rectal bleeding, anorexia, food refusal, failure to thrive, abdominal pain, and severe colic 5, 20 .
IgE-mediated CMPA has atopic manifestations such as urticaria, angioedema, vomiting, diarrhea, eczema, rhinitis, and anaphylaxis 5 . Non-IgE mediated CMPA encompasses food proteininduced enterocolitis syndrome (FPIES), food protein-induced allergic proctocolitis (FPIAP) and food protein-induced enteropathy 2, 21 . FPIES is relatively uncommon and manifests usually in infants as profuse repetitive vomiting (onset one to three hours after ingestion) and diarrhea (onset 5-10 hours) that may be accompanied by lethargy, acute and severe edema, shock and moderate failure to thrive, generally without acute respiratory and skin manifestations 2, 21 . The symptoms mimic sepsis, metabolic disease or acute abdominal problems, which lead to under-diagnosis of this condition. FPIAP, on the contrary, is a benign transient condition, which typically starts in the first few months of life while being exclusively breast fed, with blood-streaked stools and occasionally mild diarrhea with no emesis or signs of shock or failure to thrive in well-appearing infants without growth retardation and considered as one of the major causes of colitis under age one year 2, 21 . Enteropathy due to CMPA is associated with intermittent vomiting, chronic diarrhea, steatorrhea, moderate edema due to hypoalbuminemia, poor weight gain and lack of signs of shock 21 . Mixed type CMPA may present as eosinophilic esophagitis, eosinophilic gastroenteritis and eosinophilic colitis, and can manifest at any age with a male predominance and symptoms ranging from chronic abdominal pain, nausea, vomiting, dysphagia, food impaction, diarrhea to weight loss, anemia and malabsorption depending on the extent of bowel involvement 1, 21, 22 .
While some symptoms such as angioedema and atopic eczema are more likely to be seen in CMP-specific IgE positive children; the same symptoms may also appear in CMP IgE-negative patients, particularly those having gastrointestinal manifestations such as allergic proctocolitis 5, 23 . Figure 1 illustrates an algorithm for infants and children with symptoms suggestive of CMPA 20 . If CMPA is suspected, a differential diagnosis is needed including family history and physical examination as the initial step. If any of the findings presented in Table I occurs, the second step is conducting a differential diagnosis with or without laboratory evaluation, and when manifestations cannot be associated with any other cause, CMPA may be thought as a potential diagnosis 5 . CMPA diagnosis should be based on symptomatic evaluation and diagnostic elimination diet as followed by an oral challenge test after disappearance of symptoms and confirmation of CMPA diagnosis in re-appearance of symptoms 5, 8, 20 .
Diagnosis of CMPA
If CMPA is likely with relevant symptoms, elimination of CMP in the child's and/or breastfeeding mother's diet should be tried for limited time to confirm the diagnosis. The duration of a diagnostic elimination diet should be decided according to clinical manifestation; usually for 3 to 5 days if immediate clinical reactions, and 1 to 2 weeks if delayed clinical reactions are observed, while 2 to 4 weeks on a CMPfree diet before evaluation may be necessary in patients with gastrointestinal reactions 5 . If no improvement in symptoms within these timelines is achieved, then CMPA diagnosis is not likely; though, multiple food allergies and other diseases should be considered.
For diagnostic elimination in breast-fed infants, breast-feeding is continued while avoiding all milk and milk products like cheese, yogurt and butter from the maternal diet in accordance with qualified dietary counseling. If symptoms continue on breast milk despite a strict maternal 
Treatment of CMPA
The safest strategy in managing CMPA is to strictly avoid from CMP. The decision of using a substitute formula and choosing the best formula to fulfill nutritional requirements of the children with CMPA should be done mostly based on the age of the patient and the history of other food allergies 5 . The consensus recommendations for CMPA management are presented in Figure 1 20 .
For exclusively breastfed infants, diagnostic elimination involves elimination of the products containing cow's milk including cheese, yogurt and butter from the maternal diet. Breastfeeding mothers who eliminate cow's milk products from their diet for long periods should take calcium supplements and take dietary counselling to avoid nutritional deficiencies 5 .
C o w ' s m i l k -b a s e d f o r m u l a a n d a n y complementary food containing CMP should be avoided in exclusively breastfed infants. When symptoms of allergy occur in formula-fed infants, either exclusively or as a supplement to breastfeeding, they should be given a therapeutic formula that has clinically proven reduced allergenicity and high tolerability 31, 32 . Extensively hydrolyzed formula (eHF; casein or whey) and AAF are the two such alternatives recommended for formula feeding among infants with CMPA 7, 19, 31 .
e H F s a r e i n d i c a t e d i n t r e a t m e n t a n d in prevention of CMPA and tolerated by the majority of infants and children with CMPA 5, 19 . AAF is developed to overcome the hypersensitivity against residual proteins in eHF, particularly in cases with severe enteropathy or with multiple food allergies 5 . For that reason, AAF may be considered only in infants with severe reactions such as anaphylaxis, enteropathy, eosinophilic esophagitis and food protein induced enterocolitis along with cases of multiple system involvement, multiple food allergies and intolerance to eHF 5, 8, 33 . While soy-based formulae are associated with lower allergenicity than cow's milk-based formulae 34, 35 , concerns about the isoflavone (phytoestrogen) content have been raised 36 .
Accordingly, ESPGHAN and American Academy of Pediatrics (AAP) consider use of eHF and AAF for the dietary treatment of infants with CMPA as the first option if eHF is not better tolerated than soy protein-based formulae 35, 37 .
Partially hydrolyzed formulae (pHF) based on CMP, other mammalian proteins, and milk from other mammalians are not recommended 8, 25, 26, 38 .
In infants with documented CMPA and exclusively breast-fed and formula-fed, weaning food should be free of CMP until the development of tolerance is confirmed by oral challenge tests. Introduction of supplementary foods should not be delayed while should be made one by one in small amounts and only after the infant is at least 17 weeks of age, preferably while the mother is still breastfeeding 5, 39, 40 .
Among children with CMPA on elimination diet beyond the first 12 months of age, dietary supervision by a health professional specialized or trained in pediatric nutrition is recommended to decide about sufficient amounts of nutrients, proteins, calcium, vitamin D, and vitamin A in the diet and the need for a therapeutic formula or supplements to achieve a normal growth for age 41 .
Evaluation by re-challenge
While CMPA has traditionally been considered to resolve by 1 to 2 years of age, evidences to define an optimal interval before reevaluation are not sufficient 5, 8, 20 . Age, severity of a child's symptoms, and positivity of specific IgE for CMP are amongst the factors that determine the duration of exclusion 5 .
Following confirmation of CMPA diagnosis, maintenance on an elimination diet by a therapeutic formula has been recommended using for at least 6 months or until 9 to 12 months of age. Infants and children with severe immediate IgE-mediated reactions may stay on the elimination diet longer (12 or even 18 months) before re-challenge following the repeat tests specific for IgE 5 . On the basis of its correlation with persistence of allergy, high specific IgE levels are considered to be a useful predictor of patient outcome 42 , while low levels of specific IgE antibodies were shown to be associated with faster gain of milk tolerance among CMPA patients 20 . Hence, in specific IgE negative cases with mild symptoms,
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conventional approach considers a re-challenge with cow's milk after a therapeutic diet for at least 4-6 months, while up to at least 12 months in case of high-Ig E positivity or severe reactions, to avoid unnecessary prolongation of restrictive diet and the likelihood of improper growth 1, 5 .
Re-challenge may lead to severe reaction particularly if the patient had a previous severe/ life threatening reaction history, therefore a dose-titrated challenge should be performed in experienced clinic under close monitoring.
If a challenge gives positive results, usually the elimination diet is continued for 6 to 12 months. If it is negative, then the child is fully re-exposed to cow's milk. If CMP challenge test is negative, the infant may be safely moved to a standard cow's milk formula (CMF). If a child on AAF can tolerate eHF challenge, it is safe to move the infant to an eHF. If a response to either a CMP or eHF challenge test is observed, the infant should be kept on the therapeutic formula that resolved the symptomatic manifestations of CMPA 5, 8, 43 .
The prognosis of infancy and young childhood CMPA is good. Tolerance develops in up to 50% of the affected children by the age of 1 year, up to 85% by the age of 3 years, and up to 90% has become tolerant by the age of 6 years 5,17 .
Prevention of CMPA
The best approach to prevent allergy is exclusive breastfeeding for 4-6 months (17-27 weeks) 8 that has been shown to have significant protective effect against atopic dermatitis in comparison to conventional CMF 44, 45 .
No benefit of modulation of maternal diet has been shown in decreasing incidence of allergy 46,47 along with the likelihood of an unbalanced maternal diet to negatively affect one or both of fetal and maternal nutrition 8, 24 . Accordingly, recent guidelines consistently recommend not modifying maternal diet during pregnancy or lactation to prevent CMPA 2, 8, 10 .
At-risk infants should be identified by family history for atopic conditions such as CMPA, food allergy, atopic dermatitis, asthma, allergic rhinitis, and should receive a prevention diet if at risk of allergy and not exclusively breastfed. Use of hydrolyzed formulae has been recommended by the guidelines in at-risk infants who are not breastfed for the prevention of CMPA until their risk has been assessed by healthcare personnel 2, 8, 10 .
pHF has been produced to minimize sensitizing epitopes of milk proteins, by keeping peptides in sufficient size and immunogenicity to induce oral tolerance. Thus containing larger peptides than eHF, they are not suitable in treatment of CMPA 19, 48 . eHF and AAF remove allergenicity, but the loss of immunogenicity to prevent CMPA also keeps the immune system from developing tolerance to milk proteins 48 . Therefore, commonly pHF is used to prevent allergy 19 . Efficacy of using both pHF and eHF were shown in the prevention of allergy in at high risk infants 44, 49, 50 , while AAF is not recommended in prevention of CMPA 8 .
Hence experts agreed that it is difficult to assess allergy in neonates, and if exclusive breastfeeding is impossible, hydrolyzed formula (pHF or eHF) offers advantages in preventing cow's milk allergy until their risk has been assessed by a healthcare professional 8 .
There is no evidence confirming benefit from delayed introduction of solid even potentially allergenic foods beyond the age of 4-6 months to protect from allergy 5, 39 . Experts agreed that supplementary foods should be introduced one at a time in small quantities, preferably while the mother is still breastfeeding but not before the infant is at least 17 weeks of age in accordance with ESPGHAN guidelines 5 .
Probiotic supplementation of mothers during pregnancy and lactation has been indicated to be likely to prevent early infant atopy, and supplementation of eHF with prebiotics has been considered likely to decrease the occurrence allergic manifestations, such as atopic dermatitis, recurrent wheezing, and allergic urticaria in infancy 51, 52 . However, further evidence is required to recommend prebiotics safely in order to reduce atopic dermatitis incidence in routine practice 8, 53 .
Conclusion
The present consensus statement provides recommendations for the diagnosis, prevention and management of suspected CMPA in infants and children in Turkey, based on evidencebased guidelines, literature data and expert clinical experience and in accordance with socioeconomic characteristics and current healthcare policies specific to our country. Infants with a confirmed diagnosis of CMPA should maintained an elimination diet with a therapeutic formula at least for 4-6 months or until the age of 9 to 12 months, while both infants and children who have severe immediate IgE-mediated reactions may receive the elimination diet longer (12 or even 18 months) before the re-challenged following the repeat IgE-specific testing. Conventional approach considers a cow's milk re-challenge after a therapeutic diet for at least 4-6 months in case of specific IgE negativity and mild symptoms, while up to at least 12 months in case of high-Ig E positivity or severe reactions, to avoid unnecessary prolongation of restrictive diet and the likelihood of improper growth 1, 5 .
If a challenge produces positive response, the elimination diet is usually continued for another 6 to 12 months. If it is negative, then the child is re-exposed to cow's milk containing diet 5 .
Introduction of supplementary foods should not be delayed and should be made one by one in small amounts after the infant is at least 17 weeks of age, preferably while the mother is still breastfeeding 5, 39, 40 .
Prevention:
The best method to prevent infant allergy is exclusive breastfeeding for 4-6 months. There is no evidence showing the benefit of modifying maternal diet during pregnancy or lactation, delaying solid and potentially allergic foods beyond 4-6 months in at-risk infants. When breastfeeding exclusively is impossible, all at-risk infants should receive a hydrolyzed formula (pHF or eHF) that appears to be advantageous in preventing allergic conditions including cow's milk allergy until a risk assessment by a healthcare professional 8 .
Given the limited number of studies concerning epidemiology and practice patterns in CMPA in Turkey, the main limitation of the current statement seems to be the fact that present recommendations are dependent on the expert clinical opinion of the panel members rather than data on the prevalence of CMPA or the efficacy of CMPA treatment strategies.
In conclusion, the present consensus statement is the first to provide recommendations for the diagnosis, prevention and management of CMPA in infants and children in Turkey. These recommendations should assist healthcare practitioners to optimize their approaches in managing CMPA and reducing the burden of disease on the infants and the family. Given the lack of reliable objective diagnostic tools 
